Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study assessing COVID-EIG for the treatment for severe hospitalized patients

Trial Profile

A study assessing COVID-EIG for the treatment for severe hospitalized patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2020

At a glance

  • Drugs COVID-2019 immune globulins (Equine) (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2020 New trial record
    • 11 Mar 2020 According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020.

Trial Overview

Purpose

This study will be evaluating COVID-EIG for the treatment for severe hospitalized patients.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female
  • Age Group adult

Trial Details

Organisations

  • Affiliations Emergent BioSolutions

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I/II
  • Location Unknown
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
COVID-2019 immune globulins (Equine)Primary Drug
-
-

Trial History

Event Date Event Type Comment
26 Mar 2020 New trial record New trial record Updated 26 Mar 2020
11 Mar 2020 Other trial event According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020. Updated 26 Mar 2020

References

  1. Emergent BioSolutions. Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease. Media-Rel 2020;.

    Media Release
  2. Emergent BioSolutions. Emergent BioSolutions Reports Financial Results for First Quarter 2020. Media-Rel 2020;.

    Media Release
Back to top